Investors should always pay attention to insider buying.
After all, no one knows their company like a CEO, CFO, or a Director. Over the last few days, we’ve spotted solid insider buying in the following stocks.
Granite Construction (GVA)
Granite Construction Incorporated operates as an infrastructure contractor and a construction materials producer in the United States. The company operates through Transportation, Water, Specialty, and Materials segments.
The company’s CFO and a director just bought $163,000 worth of stock on November 5, 2019. That follows $500,000 worth of insider buying in August and September. All after the stock fell to a multi-year low of $23.79 after posting quarterly results that were well below expectations.
“During the third quarter, strong core operational performance was dampened by a negative contribution from the heavy civil operating group primarily driven by disputed work,” Roberts said. “As we restore balance in heavy civil, a critical piece of the puzzle is resolution of ongoing disputes which continue to have a distorted impact on our cash flows and earnings.”
Data I/O Corporation (DAIO)
Data I/O Corporation designs, manufactures, and sells programming systems and services for electronic device manufacturers in the United States, Europe, and internationally.
Between November 6 and 8, 2019, director John D. Delafield bought a total of 128,446 shares between $3.54 and $3.70 for $464,507. All after the stock plummeted to a multi-year low of $3.23. Better, the company was just awarded a 2019 Global Technology Award in the category of Programming for its new PSV2800, according to the company’s press release.
“With billions of devices produced each year for the industrial controls, Internet of Things, medical and automotive markets, electronic manufactures need a high speed reliable automated programming solution to meet quality, volume and cost requirements.”
“The PSV2800 is an ideal fit for these dedicated high-volume applications providing customers with the high performance and reliability Data I/O is known for at the lowest total cost of ownership,” said Anthony Ambrose, President and CEO of Data I/O Corporation. “We are excited to be recognized for our innovative technology from industry leaders with the Global Technology Award for programming the PSV2800.”
OncoCyte Corporation (OCX)
OncoCyte Corporation engages in the development and commercialization of non-invasive blood-based diagnostic tests for the early detection of cancer. The company is developing DetermaVu, a non-invasive molecular lung cancer confirmatory diagnostic that is administered to patients as a blood test. It also develops diagnostic tests based on liquid biopsies for detecting breast cancer. On November 13, 2019, Broadwood Partners, a 10% owner, bought 1,176,471 shares for just over $2 million.